Publications by authors named "J Garweg"
Purpose: To test to what degree retinal fluid (RF) after the loading phase and at the end of year 1 predicts long-term functional outcomes in neovascular macular degeneration (nAMD), as do macular (MA) atrophy, treatment density and treatment interval extension.
Methods: In this retrospective single-center cohort study, a consecutive series of eyes with treatment-naïve nAMD followed under a treat-and-extend (T&E) protocol followed over ≥2 years. Best-corrected visual acuity (BCVA), presence of retinal fluid (RF) and macular atrophy (MA) were registered along with central retinal thickness (CRT) and treatment density over time.
Article Synopsis
- Diabetic macular edema (DME) is a serious vision impairment often treated with anti-VEGF agents, but some patients don't respond well; this study tests the effectiveness of the intravitreal dexamethasone (DEX) implant as a second-line option for those not responding adequately or facing high treatment burdens.
- Conducted across seven Swiss clinical sites, the retrospective study analyzed 95 eyes from patients who had previously received anti-VEGF therapy for at least six months before starting DEX treatment, focusing on visual acuity and retinal swelling.
- Results showed a significant reduction in anti-VEGF injections after DEX treatment and improvement in retinal thickness, with BCVA remaining stable, while some patients experienced side effects requiring additional
Aims/hypothesis: Diabetic retinopathy is characterised by neuroinflammation that drives neuronal and vascular degenerative pathology, which in many individuals can lead to retinal ischaemia and neovascularisation. Infiltrating macrophages and activated retina-resident microglia have been implicated in the progression of diabetic retinopathy, although the distinct roles of these immune cells remain ill-defined. Our aim was to clarify the distinct roles of macrophages/microglia in the pathogenesis of proliferative ischaemic retinopathies.
View Article and Find Full Text PDFPurpose: To assess the impact of ocular confounding factors on aqueous humor (AH) proteomic and metabolomic analyses for retinal disease characterization.
Methods: This study recruited 138 subjects (eyes): 102 with neovascular age-related macular degeneration (nAMD), 18 with diabetic macular edema (DME), and 18 with cataract (control group). AH samples underwent analysis using Olink Target 96 proteomics and Metabolon's metabolomics platform Data analysis included correlation, differential abundance, and gene-set analysis.
Article Synopsis
- Janus kinase (JAK) inhibitors are being explored for treating patients with noninfectious uveitis (NIU) who do not respond to traditional treatments, as highlighted in recent studies up to October 2023.
- JAK inhibitors affect multiple cytokines compared to biological agents that target specific ones, showing promise in managing immune-related diseases, although their safety profiles are still unclear and require further investigation.
- Currently, JAK inhibitors are viewed as experimental and are recommended mainly for severe, sight-threatening cases of uveitis that don’t respond to standard therapies.